Your browser doesn't support javascript.
loading
Phase II study of the c-MET inhibitor tivantinib (ARQ 197) in patients with relapsed or relapsed/refractory multiple myeloma.
Baljevic, Muhamed; Zaman, Shadia; Baladandayuthapani, Veerabhadran; Lin, Yan Heather; de Partovi, Claudia Morales; Berkova, Zuzana; Amini, Behrang; Thomas, Sheeba K; Shah, Jatin J; Weber, Donna M; Fu, Min; Cleeland, Charles S; Wang, Xin Shelley; Stellrecht, Christine M; Davis, Richard E; Gandhi, Varsha; Orlowski, Robert Z.
Affiliation
  • Baljevic M; Division of Hematology & Oncology, The University of Nebraska Medical Center, Omaha, NE, USA.
  • Zaman S; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Baladandayuthapani V; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Lin YH; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • de Partovi CM; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Berkova Z; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Amini B; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Thomas SK; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Shah JJ; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Weber DM; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fu M; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Cleeland CS; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wang XS; Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Stellrecht CM; Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Davis RE; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gandhi V; Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Orlowski RZ; Department of Experimental Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ann Hematol ; 96(6): 977-985, 2017 Jun.
Article in En | MEDLINE | ID: mdl-28337527
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrrolidinones / Quinolines / Proto-Oncogene Proteins c-met / Multiple Myeloma Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Hematol Journal subject: HEMATOLOGIA Year: 2017 Document type: Article Affiliation country: United States Country of publication: Germany
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Pyrrolidinones / Quinolines / Proto-Oncogene Proteins c-met / Multiple Myeloma Limits: Aged / Female / Humans / Male / Middle aged Language: En Journal: Ann Hematol Journal subject: HEMATOLOGIA Year: 2017 Document type: Article Affiliation country: United States Country of publication: Germany